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PARDIOVASCULAR GENOMIC MEDICINE
ardiovascular Proteomics
ools to Develop Novel Biomarkers and Potential Applications
ara Arab, PHD,*¶ Anthony O. Gramolini, PHD,*† Peipei Ping, PHD,# Thomas Kislinger, PHD,‡§
rian Stanley, PHD,** Jennifer van Eyk, PHD,** Maral Ouzounian, MD,* David H. MacLennan, PHD,*‡
ndrew Emili, PHD,*‡ Peter P. Liu, MD*¶
oronto, Ontario, Canada; Los Angeles, California; and Baltimore, Maryland
Proteomics is the new systems biological approach to the study of proteins and protein
variation on a large scale as a result of biological processes and perturbations. The field is
undergoing a dramatic transformation, owing to the completion and annotation of the human
genome as well as technological advances to study proteins on a large scale. The new science
of proteomics can potentially yield novel biomarkers reflecting cardiovascular disease,
establish earlier detection strategies, and monitor responses to therapy. Technological
advances permit the unprecedented large-scale identification of peptide sequences in a
biological sample with mass spectrometry, whereas gel-based techniques provide further
refinement on the status of post-translational modification. The application of high
throughput protein evaluation with a subset of predefined targets, identified through
proteomics, microarray profiling, and pathway analysis in animal models and human tissues,
is gaining momentum in research and clinical applications. Proteomic analysis has provided
important insights into ischemic heart disease, heart failure, and cardiovascular pathophysiology.
The combination of proteomic biomarkers with clinical phenotypes and genetic haplotype
information can lead to a more precise diagnosis and therapy on an individual basis—the
fundamental premise of “personalized medicine.” (J Am Coll Cardiol 2006;48:1733–41)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.063© 2006 by the American College of Cardiology Foundation
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rhe social, economic, and human costs of cardiovascular
isease continue to escalate. Despite the amazing scientific
dvances in the physical and biological sciences, the number
f effective cardiovascular therapies and viable therapeutic
argets remains surprisingly limited. The number of useful
ardiovascular biomarkers is even fewer.
To gain an insight into the disease processes in individual
atients, their unique response to etiological risk factors,
nd their stages of disease progression, an array of diagnostic
ools such as haplotype analysis for genes of susceptibility,
ene expression arrays (transcriptome), metabolic profiling
metabolome), and new protein profiling tools (proteome)
re moving from the bench to the bedside. These technol-
gies, sometimes referred to as the “new science,” might
rovide the opportunity to facilitate the transition from the
urrent paradigms of generic clinical decision-making to the
ew era of a more “personalized medicine.”
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an, Gramolini, Emili, and Liu receive a partnership research grant through Genome
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insburg, MD, PhD.s
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ccepted June 5, 2006.“Proteomics” was coined by Australian researchers a decade
go to describe all the proteins expressed by the genome that
efines an organism. Proteomics is thus the study of the
arge-scale expression, function, and interaction of the com-
lement of proteins in an organism in health and disease.
ecent advances in proteomic technologies permit the
valuation of systematic changes in protein expression in
esponse to intrinsic or extrinsic perturbations to the bio-
ogic system, for example, those that occur in cardiovascular
isease. Proteomics is a potential tool for the discovery and
pplication of novel biomarkers in diagnosis of the inception
nd progression of heart disease, which might then affect
revention and therapy.
Proteomics differs from “genomics” in both complexity
nd dynamic variability. Whereas the genome is relatively
onstant, the proteome is constantly changing according to
he moment-to-moment interactions between the genome
nd the environment. It differs from “metabolomics,” or
etabolic profiling, because the latter details the metabolic
ntermediates as a result of protein enzymatic actions on the
nergetic substrates. Proteomics differs from traditional
protein chemistry” in that the latter studies mainly the
hemical properties of specific families of proteins, whereas
roteomics studies the large-scale interaction of the protein
epertoire within an organism. Proteomic biomarkers also
iffer from traditional biochemical markers that we cur-
ently use clinically, in that multiple interacting protein
pecies are evaluated simultaneously to reflect the re-
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he environment.
Proteomic analysis provides a unique opportunity to under-
tand the pathophysiology of disease in a non-biased manner.
t also permits the development of a suite of candidate
iomarkers for the diagnosis, staging, and tracking of disease.
et no technology, however sophisticated, can provide
cientific insights and advances without the accompaniment
f proper clinical information and the biological context.
PPLICATIONS OF
ROTEOMICS IN CARDIOVASCULAR DISEASE
nderstanding of novel pathophysiological mechanisms.
ne major benefit afforded by current large-scale proteomic
echnologies, regardless of method or combination of meth-
ds used, is the potential for a greater understanding of the
ellular processes that are responsible for the transition to
isease phenotypes. By profiling the changes in the total
etectable protein pool of the heart in a time- and disease-
ependent manner, it is potentially possible to evaluate the
hanges in critical pathways that might be present early in
he disease process, before the onset of clinical symptoms or
unctional perturbations and during disease progression.
he knowledge might also help to distinguish etiological
ackground, individualized pathophysiology, and in turn,
rognosis and individualized therapy. The new proteomic
ools, with systems biology approaches, have the potential to
nravel greater complexity in previously unexplored signal-
ng networks, leading to improved biological understanding
nd evaluation as potential novel biomarkers.
In addition to quantification of protein levels, large-scale
roteomic studies have the ability to detect post-translational
odifications (PTMs). Although cataloguing PTMs, such as
hosphorylation, sulphation, glycosylation, hydroxylation, ni-
rosylation, N-methylation, carboxymethylation, acetylation,
renylation, and N-myristoylation, is still early in development,
rogress has been rapid and shows promise.
dentification of diagnostic/prognostic biomarkers for
ardiovascular disease. Cardiovascular diseases tradition-
lly have relied on epidemiological associations to identify
iagnostic and prognostic risk factors, such as hypercholes-
erolemia and hypertension in populations. Only a handful
f biomarkers such as troponin for acute coronary syn-
romes or brain natriuretic peptide for acute heart failure
re currently used to diagnose or prognosticate individual
atients.
With advances in proteomic technologies, the approach
f biomarker identification now shifts from large-scale
Abbreviations and Acronyms
ELISA  enzyme-linked immunoadsorbent assay
HUPO  Human Proteomic Organisation
PTM  post-translational modificationpidemiologic associations to association between the dis- dase phenotype and specific genomic or proteomic patterns.
hese novel biomarkers can be developed for increased
recision in diagnosis, identification of susceptibility to
omplications, and prognosis tailored to individuals and
ubclassification of disease on the basis of pathophysiolog-
cal manifestations. Because individual biomarkers will have
imited sensitivity and specificity, proteomics affords the
pportunity to identify a panel of complementary biomar-
ers that will have more robust operational characteristics.
Whereas a good diagnostic marker might or might not
ave known biological relevance to the disease process (e.g.,
-reactive protein might behave as a good risk factor by
ssociation without having been proven to have a causative
ole in disease formation), we believe that most useful or
pecific diagnostic/prognostic/efficacy biomarkers eventually
ill be shown to have biological relevance to the disease
ondition. Therefore, in our search for novel biomarkers for
eart failure or atherosclerosis, we look for convergence of
roteomic patterns observed from both relevant animal
odels of the disease and from robust clinical phenotypes
howing the same disease. Potential biomarkers can be iden-
ified with timed evaluation of animal models of disease
evelopment. The subsequent validation of these candidate
uites of biomarkers will be most critical to distinguish those
hat will be robust for clinical application versus those that do
ot provide adequate sensitivity or specificity or biological
nsight into disease progression.
dentification of novel therapeutic targets. The combi-
ation of animal model and/or clinical studies will naturally
ead to novel insights into the biology of the disease under
tudy. Additional in-depth evaluation of new biomarker
athways will identify a number of potential novel targets
elevant to the disease. Depending on the nature of these
argets and ease with which the disease can be manipulated
herapeutically, proteomic tools allow for screening of tar-
ets, their ligands and interacting partners, and even ther-
peutic candidates and predictors of response. Overall,
edical diagnostics will most likely be the first goals to be
chieved from proteomic technologies. It will take longer
o evaluate therapeutic target function and identify safe
nd effective modulators that are suitable for clinical
evelopment.
XAMPLES OF PROTEOMIC BIOMARKER
ANDIDATES AND IMPLICATIONS FOR APPLICATION
merging proteomic biomarkers as applied to ischemic
eart disease. The evaluation of tissues in models of
yocardial ischemia has confirmed traditional protein
arkers of ischemia and tissue defense and injury. In a
abbit model of ischemia reperfusion, 2-dimensional (2-D)
el analysis revealed systematic perturbations of several
lasses of known and novel proteins. These include sarco-
ere and cytoskeleton proteins (myosin light chain and
roponin C); redox enzymes (reduced nicotinamide adenine
inucleotide [NADH] ubiquinon oxidoreductase com-
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November 7, 2006:1733–41 Cardiovascular Proteomics Reviewlexes); energy metabolism (including creatine kinase iso-
orms); and stress response proteins (1). More sustained
schemia in a pig model also revealed systematic alterations
n other families of proteins. These included elevations of
athepsin B and D, heat shock protein Hsc73, and beclin1,
ll associated with autophagy of tissues (2). These protein
hanges are accompanied by a decrease in apoptosis, sug-
esting that these proteins are activated to protect the
yocardial tissue against ischemia.
Plasma sample analysis of patients with acute coronary
yndromes has also identified interesting associated biomar-
ers to date. Two-dimensional gel electrophoresis analysis
f plasma from patients with myocardial infarction com-
ared with unaffected individuals showed a reduction of
amilies of alpha(1)-antitrypsin, fibrinogen, and apoli-
oprotein A-I isoforms in myocardial infarction or un-
table angina (3). In contrast, gamma-immunoglobulin
eavy chains were increased in acute coronary syndrome.
ven for the traditional troponin I and T used for current
iagnosis of myocardial injury, Labugger et al. (4) have
dentified multiple post-translationally modified, truncated,
r degraded protein forms that are reflective of the under-
ying degree of injury.
merging proteomic insights in heart failure. Analysis of
entricular proteomic changes during the initial inception,
evelopment, and progression to heart failure revealed
arge-scale pattern differences (5). Major alterations ob-
erved in heart failure relate to inflammation, calcium
ignaling, growth and deaths, and cytoskeletal/matrix re-
odeling targets. In more specific genetic models of car-
iomyopathy, such as Rac1 transgenic mice, proteins regu-
ated in heart failure include creatine kinase M-chain,
ubulin beta-chain, manganese superoxide dismutase, and
alate dehydrogenase (6). Similarly, in canine models of
cute heart failure due to ischemia, certain proteins are
p-regulated, including nicotinamide adenine dinucleotide
NAD) isocitrate dehydrogenase and mitochondrial aden-
sine triphosphate (ATP) synthase D chain, whereas crea-
ine kinase M chain and myosin light chain-1 were de-
reased (7).
In terms of plasma, the aforementioned protein candi-
ates are also consistent with the efforts of the Human
roteomic Organisation (HUPO) to analyze the human
lasma subproteome systematically. Initial analysis identi-
ed families of proteins involved in inflammation, signaling,
rowth and differentiation, cytoskeletal, channel/receptors,
nd remodeling processes (8).
ROTEOMIC TECHNOLOGICAL PLATFORMS
el-based proteomic approaches. In cardiovascular pro-
eomics, much of the work to date has been performed
hrough high-quality 2-D gel-based electrophoresis of tis-
ue or blood samples (9–11). The principles of the gel-based
echnique involve separation of proteins in the first dimen-
ion according to their charge properties (isoelectric point ppI]) under denaturing conditions, followed by their sepa-
ation in the second dimension according to their relative
olecular mass by sodium dodecylsulfate polyacrylamide gel
lectrophoresis (SDS-PAGE) (12–14).
Studies using gel-based technologies have yielded exam-
les of novel insights into the mechanisms of ischemic
yocardial disease, particularly the post-translational modi-
cations of abundant proteins, such as troponin (10). Gel-
ased techniques have the additional advantages of ease of
se and cost efficiency. However, the technique is con-
trained in terms of depth of protein coverage. Given that
ny biological protein sample displays substantial com-
lexity and can span protein expression levels of up to 10
rders of magnitude, gel-based proteomic techniques tend
o bias toward detection of high-abundance housekeeping
nzymes, with reduced detection of low-abundance
embrane-bound proteins or those with extremes in iso-
lectric point (15,16). However, recent advances in selective
xpansion of narrow pH ranges have increased significantly
he resolution of this technique (10) (Fig. 1). The ability to
eplete dominating protein species such as albumin in the
lood and contractile and structural proteins in the myocar-
ium has also facilitated the detection of smaller molecular
eight species important in regulation and signaling. In the
urrent era, gel-based techniques are particularly useful for
pecific target validation when the protein species are
nown, for example, through identification by mass spec-
rometry. They are also suitable for the evaluation of PTM.
sotope affinity tagged techniques. A complementary ap-
roach to the gel-based proteomic technique is the use of
sotope affinity tags to increase the sensitivity of detection
f smaller peptide fragments. This can be done with or
ithout prior protein or organelle separation. The first
reakthrough in quantifying differences in protein compo-
ition between 2 samples was the development of isotope
oded affinity tags (ICAT), which selectively label cysteine
esidues of peptide fragments following tryptic digest of the
rotein sample. The labeled fraction is then selectively
nalyzed and has been found to increase significantly the
epth of protein coverage but is limited by selective labeling.
more recent improvement led to the iTRAQ technique
Applied Biosystems, Foster City, California) in which
very tryptic fragment is labeled, thus increasing the confi-
ence in the protein species identified. The iTRAQ tech-
ique also allows for measurement of absolute rather than
elative changes in protein composition, thereby permitting
omparisons across multiple samples.
el-free “shotgun” proteomic techniques with tandem
ass spectrometry. The more recent use of gel-free systems,
hich couple high-efficiency liquid chromatography separation
rocedures with automated tandem mass spectrometry, allows
or large-scale “shotgun” sequencing of complex mixtures
5,17,18). The archetypal approach, termed MudPIT (for
ultidimensional protein identification technology) (19),
as proven to be effective for investigating global changes in
rotein expression as a function of development and disease
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Cardiovascular Proteomics Review November 7, 2006:1733–41Fig. 2) (20–22). The advantages in terms of scale and
fficacy are, however, balanced by a more complex algorithm
nd less direct means to gain insight into PTM or isoform
hifts.
In contrast to 2-D electrophoretic techniques in which
igh-abundance protein species predominate, the gel-free
shotgun” profiling procedures provide much more exten-
ive coverage with orders of magnitude increase in resolu-
ion. The tandem approach permits peptide species identi-
cation and also semi-quantitative estimation of the relative
bundance. Current efforts are focused on adapting data
ining algorithms, which can be trained to find specific
igure 1. Large-scale protein analysis of myocytes can be done with 2-dim
dentified on the basis of molecular weight and pH. However, to improve
rocessing conditions (e.g., expanding the pH range by selective isoelectr
tanley et al. [37]). ASB  amidosulfobetaine; SDS PAGE  sodium do
igure 2. “Shotgun” proteomic analysis combining liquid chromatograp
dentification technology (MudPIT). In this approach, proteins are enzym
everse phase, and the peptide fragments are sprayed through high voltage
ompared with existing databases to search for their identity. HPLC high-pres
CX  strong cation exchange.eatures to distinguish between or classify new samples.
hotgun techniques require typically rigorous statistical
pproaches to evaluate the significance of any predicted
atterns, owing to the volume of data analyzed and the
azards of multiple comparisons.
Shotgun tandem mass spectrometry technique currently
rovides the greatest depth of protein coverage and widest
ynamic range of size of proteins identified. Once the
andidates are identified, validation can be done with gel-based
pproaches or dedicated protein arrays.
rotein arrays in targeted sample analysis. In contrast to
he system biology approaches in which global proteomic
onal gel electrophoresis (2-DE), where the proteins can be separated and
solution and to achieve greater protein separation, optimization of the gel
] focusing) helps to improve the resolution significantly (for details, see
lsulfate polyacrylamide gel electrophoresis.
ith mass spectrometry (LC-MS) or so-called multidimensional protein
lly digested and subjected to fractionation through cation exchange and
e mass spectrometer. The unique emerging spectra are then recorded andensi
the rehy w
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sure liquid chromatography; MSmass spectometry; RP reverse phase;
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November 7, 2006:1733–41 Cardiovascular Proteomics Reviewatterns are determined, it is now possible to interrogate a
ample with a panel of a specified set of protein targets with
ustomized protein chips or arrays. Different platforms of
rotein microarrays are now readily accessible. A popular
latform is the forward phase protein microarrays or anti-
ody arrays, which consist of a series of immobilized
ntibodies on a membrane or solid media to provide relative
rotein expression levels for a specific sample (23,24). This
ethod is particularly useful in evaluating a large number of
imilar samples in a high throughput manner, for a small
umber of specific protein targets. However, different anti-
ody affinities and microreaction kinetics might lead to false
eadings when the entire array is processed under identical
onditions.
The recent development of reverse phase protein mi-
roarrays provides an alternative to classic antibody arrays.
he reverse phase protein microarrays are fabricated by
epositing small volumes of a large number of protein
amples or cell lysates onto a high protein-binding substra-
um with a robotic precision spotter. Each protein mi-
rospot contains the full complement of the representa-
ive sample, including phosphorylated analytes, as
ppropriate. Because thousands of samples can be spotted
n high density onto a single slide, a large number of
amples can be monitored simultaneously (25). However,
ecause the same antibody is being used, the comparisons
etween samples will be more valid (26). Protein microar-
ays could be used to screen binding of specific inhibitors or
igands to receptors, evaluation of enzymatic activity, protein–
rotein, protein–lipid, and protein–DNA interaction pro-
igure 3. Cluster analysis of mouse myocardial peptide fractions emerg
icrosomal, mitochondrial, and nuclear fractions. The peptide localization
ore abundant in the microsomal fraction, whereas transcription factors
udPIT  multidimensional protein identification technology.ling in answering a variety of biological questions. Inter- istingly, autoantibodies can also be detected with reverse
rrays, which is particularly useful for the investigation of
utoimmune related disorders such as cardiomyopathies.
lassical enzyme-linked immunosorbent assays. To
uantify specific proteins in a large number of samples with
igh sensitivity and precision, the classic enzyme-linked
mmunoadsorbent assay (ELISA) or its variation is still the
eliable standard. The ELISA immunoassay requires the
vailability of a specific primary antibody to the antigen of
nterest. The antibody-antigen complexes are then captured
nto a solid surface, and the antibody is in turn conjugated
o an enzyme capable of generating a colored substrate for
ight detection and quantification against a standard.
The ELISAs are extremely sensitive, capable of detecting
roteins in the picomolar to nanomolar ranges (1012 to
09 mol/l), with short assay time and high throughput.
owever, ELISA by definition requires the prior availabil-
ty of a high affinity specific antibody. Therefore, ELISAs
re excellent tools to complement the discovery platforms
iscussed previously. To evaluate biomarkers in large sam-
les of clinical materials, the development of appropriate
LISAs for the protein targets with high affinity antibodies
s an essential part of the program.
ROTEOMIC PROCESSING CONSIDERATIONS
mportance of considering subproteomes. The ability to
ifferentiate individual species of peptides by any method is
ependent on the number of peptides in the sample. To
nalyze any protein sample in depth and maximize the yield,
om “shotgun” processing. The peptides naturally cluster into cytosolic,
rs functional specificity, such that the calcium regulatory proteins are much
the nuclear-specific fractions. Ca2  calcium; GO  Gene Ontology;ing fr
confet is important to consider fractionating the sample into
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Cardiovascular Proteomics Review November 7, 2006:1733–41ubproteomes (Fig. 3). The serial analysis of the subpro-
eome components in a complex protein mixture provides a
uch more balanced and detailed portrait of the sample
eing analyzed. This is particularly true for the myocardium,
here large amounts of structural and mitochondrial pro-
eins need to be separated first, to allow the in-depth
nalysis of individual subproteomes. However, the caveat is
hat clean separation of the subproteomes might not always
e possible, and cross contamination might take place.
herefore, care must be taken to ensure that existing
rotocols or commercial products are performing equally
ell on cardiac myocytes as they do on other non filamen-
ous cells or tissues.
ombinatorial genomic and proteomic analysis. To pro-
ide a biological context for the large-scale bioinformatic
nalysis of proteomic samples, we have been combining
xpression array and proteomic data from the same samples
o maximize the confidence of the changes observed and to
inimize the false positive rates. This significantly improved
igure 4. Comparison of microarray and proteomic informatic analysis o
hereas green color indicates down-regulation. The result shows that the
owever, there are also very unique species that are differentially reg
ranscriptosomic and proteomic approaches are complementary and not d
essenger ribonucleic acid. Reprinted with permission from Kislinger
ifferentiation. Mol Cell Proteomics 2005;4:887–901.ur ability to piece together complex network of pathways bonnecting the cell surface, genome, and subproteomes in both
ormal and diseased states. Our results indicate that there is a
ignificant consonance of the transcriptosomic with proteomic
hanges (Fig. 4). The combination of approaches helps to
rioritize the importance of various families of interacting
athways for further evaluation. However, this approach
oes not capture in detail the protein PTMs and processing
hat constantly alter the target function. This type of
omparison also assumes equal breakdown and synthesis of
roteins at equilibrium, which might or might not be true
or individual proteins at any given time.
TRATEGIES FOR THE DISCOVERY
F BIOMARKERS IN PLASMA OR SERA
ccessible protein biomarkers of both normal and disease
tate are pivotal for a successful diagnostic/prognostic pro-
ram, particularly if the disease state might be characterized
y distinct fingerprints of the circulating proteins. Indeed,
scle cell development in culture. Red color denotes gene up-regulation,
a reasonable correspondence of genes seen in microarray and proteomics.
between gene expression and protein presence. This shows that the
tive. DNA  deoxyribonucleic acid; GO  Gene Ontology; mRNA 
ramolini A, Pan Y, et al. Proteome dynamics during C2Cl2 myoblastf mu
re is
ulated
uplicalood represents one of the most accessible sources for
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November 7, 2006:1733–41 Cardiovascular Proteomics Reviewiomarkers and would have broad clinical significance.
ortunately the cardiovascular system is in constant intimate
ontact with the blood, making blood-based biomarker
iscovery a particularly worthwhile approach. However,
ther fluids, such as the urine, can also serve as potential
ources in selected situations.
The choice of serum or plasma is often based on practical
onsiderations of ease of sample collection and processing
nd whether anticoagulated containers are readily available.
dditional considerations include whether the target pro-
eins are involved or bound to the coagulation cascade,
here plasma samples are needed, or whether there are
nterfering components in the plasma, where serum will be
referred. In practice, consideration of a uniform blood
ollection protocol to ensure consistency is more important
han deciding whether it should be serum or plasma.
Although serum or plasma samples provide an excellent
ource of materials for proteomic analysis, the complexity of
rotein composition makes direct protein profiling from the
lood extremely challenging. Plasma contains a dynamic
ange of protein concentrations from 55,000,000,000 pg/ml
e.g., albumin) to 1 to 5 pg/ml (e.g., IL-6), with a considerable
umber of proteins in between. A rough estimate of the
igure 5. Screening or validation of protein peptide markers can again be
HPLC), followed by mass spectrometer analysis. However, ability to remo
acilitate the detection of smaller peptide species with higher sensitivity.umber of proteins in human blood is over 106 different tolecules representing products of about 25,000 to 30,000
enes (27). This extreme range in protein number and
oncentration demonstrates the challenge of identifying
ppropriate biomarkers in the blood. We discuss here the
ros and cons of different approaches to blood-based bio-
arker discovery (Fig. 5).
lobal approach with blood sample as the discovery
ool. Although the direct analysis of the whole blood
roteome to identify potential biomarkers is the most logical
nd intuitive starting point, the number of candidates will
e restricted to abundant proteins, owing to limitations of
urrent technologies. The combination of more sophisti-
ated methods to deplete highly abundant proteins, with the
se of capillary electrophoresis to detect low molecular
eight proteins, might yield more proteomic biomarker
andidates with time. The number of detectable proteins in
lasma has risen dramatically from 40 proteins in 1975 (28)
o over 3,000 in recent studies (29). Albumin depletion
echniques have been used relatively successfully to improve
he yield of lower molecular weight species in the plasma
30,31). However, the potential loss of albumin bound
arkers or proteins that are non-specifically bound to either
he column matrix or the extracting antibodies are the
ucted after sample separation with high-pressure liquid chromatography
erabundant species such as albumin or immunoglobulins will significantlycondrade-offs. Current challenges also include bioinformatic
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Cardiovascular Proteomics Review November 7, 2006:1733–41nalysis to identify unique patterns of biomarkers that can
ccurately distinguish disease from normal, stage the dis-
ase, and provide prognostic information (32–34).
argeted approach with discovery made in model sys-
ems first, then validation in blood. This approach to
iomarker identification is based on the more traditional
ypotheses-driven evaluation of specific candidates either
n the basis of a biological rationale or analysis of candidates
erived from other sources and then validated in blood
amples. One way of approaching candidate biomarker
iscovery is the use of an appropriate repertoire of animal
odel systems. For example, in our program to discover
ovel biomarkers for heart failure, particularly those that
ight be specific for early, mid, and late stages of the
isease, we use multiple genetic and acquired models of
eart failure in murine and other animal species. The result
f informatic analysis from these models is then integrated
ith tissue analysis from patients or explanted hearts with
dvanced forms of heart failure. This approach generates a
arge number of biomarker candidates in a biological,
emporal, and clinically relevant context and permits the
alidation of these candidates in the serum or plasma of
ppropriately selected patient cohorts in replicates.
EMAINING CHALLENGES IN THE
EARCH FOR NOVEL PROTEOMIC BIOMARKERS
s the application of proteomics evolves in cardiovascular
edicine, many challenges remain. For example, what are
he advantages and trade-offs of the different technology
latforms in evaluating the cardiovascular proteome? Is a
ombination approach better than any one platform alone?
hat should be a common protocol for blood sample
andling and processing? What is the influence of standard
ardiovascular drugs on the blood proteome? How do we
ntegrate current protein data (35) with biomarker data from
ifferent investigators?
To coordinate communication amongst investigators in-
erested in proteomics and to answer some of these ques-
ions in general for the entire proteomic community,
UPO was formed in 2001 with the objective of coordi-
ating the global proteomic discoveries after the completion
f the Human Genome Project (35,36). A cardiovascular
nitiative to help in answering these questions specifically
or the cardiovascular proteome has also been established
37). This will help to coordinate the efforts of investigators
n the field to solve these problems as a community and to
evelop common standards for the purpose of data ex-
hange, pooling, and discovery.
ONCLUSIONS
s we incorporate the molecular and genomic advances into
ardiovascular medicine in the coming era of more “person-
lized medicine,” the rapid advances of proteomic technol-
gy opens a new window on the diseases that we are trying
o treat and prevent. Proteins are the ultimate biologicaleterminants of cardiovascular function and disease pheno-
ype. Proteomics will not only help to unravel some of the
emaining mysteries of biology of cardiovascular disease but
ermit the development of novel diagnostic and prognostic
iomarkers useful to better care for our patients.
However, for clinicians and clinical investigators, it is very
mportant to take advantage of the strengths of proteomics
n the context of good study design, considerations of
tatistical power, and appropriate blinding and validation.
ltimately it is the robust study result in a clinically
eaningful context that leads to clinical advances. Clinical
henotyping and accurate tracking of outcomes are still the
ornerstones of good translational medicine.
It is also important to integrate the proteomic biomarker
nformation with that available from genetic biomarkers,
uch as haplotype polymorphisms that determine disease
usceptibility, to provide an integrated risk stratification.
roteomic biomarkers need to also be coordinated with
raditional biochemical markers and clinical and image-
ased phenotype information, as an integrated database to
ake clinical decisions. No diagnostic tool, however accu-
ate and powerful, can supplant the importance of a good
linical history and traditional phenotype information to
stablish the pre-test likelihood for any test. However, the
evelopment and validation of clinically relevant proteomic
iomarker tools will likely provide the important informa-
ion on early diagnosis, prognosis, and treatment efficacy on
ardiovascular disease beyond what we can provide today
nd pave the way for personalized medicine of tomorrow.
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